Home » Newsletters » BioWorld Science

BioWorld Science

April 16, 2012

View Archived Issues

Roche divulges new tyrosine-protein kinase JAK inhibitors

Novel aptamer oligonucleotides designed in Italy

Bayer Schering discovers novel vasopressin receptor ligands

New CYPXVII inhibitors synthesized at Novartis

Purdue Pharma patents new sodium channel antagonists

Recombinant heat shock protein reduces atherogenesis in preclinical tests

AstraZeneca launches once-daily antihypertensive in U.S.

Exelixis reports novel PI3K-delta inhibitors

Novel GlyT1 inhibitors developed in Japan

Merck & Co. presents novel PDK1 inhibitors

New melanin-concentrating hormone receptor antagonists identified

New candidate cancer therapies under development at AstraZeneca

New cancer immunotherapy targets ALK-1 and VEGF pathways

GSK AMPK activators are active in diabetes and obesity models

Antimitotic cancer therapy shows promise in vivo and in vitro

Korean FDA clears phase II trial of ViroMed pain medicine

Gliolan gets Australian orphan drug status

Phase I/II ProSavin trial meets primary endpoint

AbGenomics presents antibody conjugates with anticancer activity

Eisai launches new formulation of rufinamide in U.K.

Novel Astellas histone deacetylase inhibitor has encouraging pharmacokinetics

Quantum Genomics launches first clinical study of its lead antihypertensive drug

GW confirms milestone payment from Almirall

Biodel selects ultrarapid-acting insulin formulation to advance to phase II testing

Piramal Imaging acquires PET tracers from Bayer